绿叶制药抗抑郁1类创新药LY03021完成I期临床首例受试者入组

Core Viewpoint - Green Leaf Pharmaceutical Group announced the completion of the first subject enrollment in the Phase I clinical study of its self-developed innovative drug LY03021 in China, which is intended for the treatment of depression [1] Company Summary - LY03021 is classified as a first-class innovative drug and functions as a norepinephrine transporter (NET)/dopamine transporter (DAT) inhibitor and a positive allosteric modulator of the GABA A receptor [1] - The drug is specifically aimed at addressing the treatment of depression, indicating a strategic focus on mental health therapeutics [1]